

Clinical trials of SCH 530348

TrialResults-center www.trialresultscenter.org

1 percutaneous coronary intervention

Trial	Treatments	Patients	Trials design and methods
SCH 530348 vs placebo			
TRA-PCI , 2009 [NCT00132912] n=NA follow-up:	SCH 530348 3 doses: 10mg, 20mg and 40mg versus placebo	patients aged 45 years or older and undergoing non-urgent PCI or coronary angiography with planned PCI	Parallel groups double-blind

More details and results :

- antithrombotics for percutaneous coronary intervention in all type of patients at <http://www.trialresultscenter.org/go-Q63>

References

TRA-PCI, 2009:

Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009 Mar 14;373:919-28 [[19286091](#)] [10.1016/S0140-6736\(09\)60230-0](https://doi.org/10.1016/S0140-6736(09)60230-0)